# Pyxis Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pyxis-oncology

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.pyxisoncology.com
- Total disclosed funding: $195M
- Latest round: Series B (Mar 8, 2021)
- Investors on record: 21

## About

Based in Massachusetts, US, and founded in 2018 by co-founders David Steinberg, John L. Flavin, and Shaan Gandhi, Pyxis Oncology, Inc. is an immuno-oncology company with a focus on developing a new family of antibody-based immunotherapies derived from novel insights into the biology of the tumor microenvironment. In March 2021, Pyxis Oncology, Inc. raised USD 152 million in Series B financing backed by Arix Bioscience, RTW Investments, Pfizer Ventures, BVF Partners, Leaps by Bayer, Longwood Fund, Agent Capital, and Ipsen. The company is listed on Nasdaq under the symbol PYXO.

Pyxis Oncology, Inc. develops antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies with the potential to improve the condition of cancer patients.

Pyxis Oncology, Inc.'s revenue is generated from sales of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies. 

Pyxis Oncology, Inc. plans to further develop its differentiated portfolio of antibody-drug conjugates (ADC), both in-licensed from Pfizer and LegoChem Biosciences. The company will also continue advancing its immuno-oncology (I/O) pipeline to pursue a broad range of therapeutic indications.

## Funding rounds

- Series B, Mar 8, 2021, $173M — HBM Partners, Tekla Capital Management, Ipsen, Longwood Fund, Pfizer Venture Investments, Laurion Capital Management, RTW Investments, BVF Partners, RA Capital Management, Cormorant Asset Management, Acuta Capital Partners, Ridgeback Capital Management, Perceptive Advisors, Arix Bioscience, Agent Capital, Janus Henderson Investors, LifeSci Partners, Surveyor Capital, Leaps by Bayer, Logos Capital
- Series A, Jul 17, 2019, $22M — Ipsen, Longwood Fund, Agent Capital, The University of Chicago, Leaps by Bayer

## Investors

- Ipsen — Series A, Series B
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series A, Series B
- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Series A, Series B
- The University of Chicago — Series A
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series A, Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series B
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series B
- Laurion Capital Management — Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Acuta Capital Partners (https://capitalatlas.ai/funds/acuta-capital-partners) — Series B
- Ridgeback Capital Management — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- Arix Bioscience (https://capitalatlas.ai/funds/arix-bioscience) — Series B
- Janus Henderson Investors — Series B
- LifeSci Partners (https://capitalatlas.ai/funds/lifesci-partners) — Series B
- Surveyor Capital — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B